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??????????：Sarcoidosis is a systemic noncaseating epithelioid-cell granulomatous disease of unknown ori­
gin. Granulomas occurring around malignant tumors and regional lymph nodes can be caused by sarcoid re­
actions. The mechanisms underlying sarcoidosis and sarcoid reactions remain unclear. Whether increased 
uptake of fluorodeoxyglucose （FDG） in lymph nodes on positron emission tomography （PET） is caused by 
tumor metastasis, the concurrent presence of sarcoidosis, or sarcoid reactions must be determined to ensure 
proper disease staging and selection of treatment policy. We studied patients who underwent surgery for 
lung cancer and had no histopathological evidence of lymph-node metastasis in whom concurrent sarcoido­
sis or sarcoid reactions were diagnosed.
???????：In six patients who underwent surgery for primary lung cancer, granulomatous lesions were 
histopathologically studied in dissected lymph nodes and lung. Tissue sections were stained with monoclonal 
antibodies against Propionibacterium acnes （PAB antibodies）.
???????：The six patients had noncaseating epithelioid-cell granulomas in mediastinal lymph nodes and 
lung. Clinically, concurrent sarcoidosis was suspected, but the results of staining the tissue specimens with 
PAB antibodies （in granulomas, alveolar macrophages, Hamazaki-Wesenberg bodies, and lymphatic sinuses） 
suggested sarcoid reactions in 5 patients. In one patient in whom granulomas stained positive with PAB an­
tibodies, concurrent sarcoidosis was diagnosed.
???????????：In patients with lung cancer who have no distinct systemic evidence of sarcoidosis, the 
presence of noncaseating epithelioid-cell granulomas in the lung hilum or mediastinum is usually caused by 
sarcoid reactions.
???? ????： lung cancer, Propionibacterium acnes, sarcoid reactions, sarcoidosis
?????????????：
FDG：fluorodeoxyglucose
FDG-PET： 18F-Fluorodeoxyglucose positron 
emission tomography
HW：Hamazaki-Wesenberg
P. acnes：Propionibacterium acnes
SUV：standardized uptake value
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suggestive of sarcoidosis or of infectious diseases asso­
ciated with granulomatous lesions, such as tuberculo­
sis, nontuberculous mycobacteriosis, or mycosis. There 
was also no occupational or environmental exposure to 
chemical substances such as beryllium, aluminium, or 
zirconium.
T and N categories in this report were assessed ac­
cording to the TNM staging system of the Japan Lung 
Cancer Society7）. Computed tomographic （CT） scan­
ning was performed with Asteion or Aquillion （Toshi­
ba, Japan）. The patients were always supine, and 
scans were obtained with the following parameters：
slice width, 3.0-mm collimation and 3.0-mm slice inter­
val. 18F-Fluorodeoxyglucose positron emission tomog­
raphy （FDG-PET） was performed as follows. FDG 
was intravenously administered at 4.5 MBq/kg follow­
ing fasting for at least 5 hours, and early and delayed 
images were taken 50 minutes and 2 hours after FDG 
administration, respectively. FDG-PET/CT images 
were captured by a Biograph 16 （Siemens, Germany） 
or GEMINI 16 （Philips, Netherlands） system. The 
maximum standardized uptake value （SUV max） was 
evaluated for each lesion.
Monoclonal Antibodies against P. acnes
Antibodies were generated according to the protocol 
described in a laboratory manual with modifications8）. 
The details of establishing monoclonal antibodies spe­
cific against P. acnes （named PAB antibodies, IgM） 
were described previously9）. Kindly the PAB antibod­
ies were provided from Professor Y. Eishi of the De­
partment of Human Pathology, School of Medicine, To­
kyo Medical and Dental University.
Immunohistochemistry
The formalin-fixed, paraffin-embedded, lung tissue 
specimens were stained with hematoxylin and eosin. 
Serial sections of confirmed sites of noncaseating epi­
thelioid-cell granulomas were mounted on silane-coat­
ed slides. The specimens were immunohistochemically 
stained with PAB antibodies according to the protocol 
methods described previously and viewed under a 
light microscope9）. PAB-antibody-positive staining in 
granulomas, alveolar macrophages, and Hamazaki-
Wesenberg （HW） bodies, and lymphatic sinuses was 
semi-quantitatively evaluated according to the follow­
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Among various types of malignant tumors, noncase­
ating epithelioid-cell granulomas are known to rarely 
develop around tumors or in regional lymph nodes. 
Such granulomas are attributed to sarcoid reactions, 
which are considered a distinct entity from sarcoidosis, 
a systemic disease1〜4）. In patients with lung cancer, 
whether enlarged lymph nodes on imaging studies or 
increased uptake of fluorodeoxyglucose （FDG） in 
lymph nodes on positron emission tomography （PET） 
is caused by tumor metastasis, sarcoid reactions, or 
concurrent sarcoidosis must be determined to stage 
disease and formulate the treatment strategy. Several 
potential causes of sarcoid reactions in patients with 
lung cancer have been speculated, but remain to be 
established.
Sarcoidosis granulomas are specifically stained with 
monoclonal antibodies against Propionibacterium acnes 
（P. acnes） （PAB antibodies）. P. acnes is considered to 
play an important role in the development of sarcoido­
sis 5,6）. We immunostained specimens of noncaseating 
epithelioid-cell granulomas arising in the lung and re­
gional or mediastinal lymph nodes with PAB antibod­
ies in patients with primary lung cancer who under­
went surgery and had no histopathological evidence of 
lymph-node metastasis. We then assessed the involve­
ment of P. acnes, sarcoid reactions, and concurrent sar­
coidosis in the formation of granulomas in individual 
patients with lung cancer.
????????????????????
During the 5 years from January 2006 through De­
cember 2010, 443 patients with primary lung cancer 
underwent surgical resection at the Department of 
General Thoracic Surgery in our hospital. In six pa­
tients, histopathological examination of the resected 
lung and dissected lymph nodes revealed noncaseating 
epithelioid-cell granulomas in the resected lung and 
dissected lymph nodes. And there were no deposits of 
anthracotic pigment in the epithelioid-cell granulomas. 
Noncaseating epithelioid-cell granulomas found only in 
regional lymph nodes were attributed to sarcoid reac­
tions affecting only 1 organ. Patients with such granu­
lomas were excluded from the study. Preoperative ex­
aminations showed no evidence of systemic changes 
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pathological stage of lung cancer was stage IA in 3 pa­
tients and stage IIB in 3 . The postoperative tumor 
stage in the 2 patients with a preoperative diagnosis of 
stage IIIA or IIIB disease was revised to stage IIB be­
cause no lymph-node metastasis was found on opera­
tion. One patient was given a preoperative diagnosis of 
stage IIIA disease because the hilar lymph nodes 
showed increase uptake of FDG （SUV, 6 .9/7 .4） on 
FDG-PET, although no malignant cells were detected 
on endobronchial ultrasound-guided lymph-node biop­
sy. The other patient was given a preoperative diagno­
sis of stage IIIB disease because FDG-PET revealed 
increased uptake of FDG （SUV, 7.6/10.1） in the medi­
astinal and contralateral hilar lymph nodes, although 
no malignant cells were detected on endobronchial ul­
trasound-guided transbronchial needle aspiration. To 
our knowledge, clinically active sarcoidosis associated 
with lesions of the lung, eyes, heart, or skin has not 
been reported previously.
Table 2 shows the results of immunostaining with 
PAB antibodies. In one of the six patients, PAB-anti­
body staining was negative in granulomas in the lung, 
but positive in granulomas in dissected lymph nodes. 
ing 3-grade scale：-, ＋, and ＋＋.
This study was approved by the Bioethics Commit­
tee Dokkyo Medical University and a signed consent 
form was obtained from each patient.
???????
Among 443 patients with primary lung cancer who 
underwent surgical resection at the Department of Re­
spiratory Surgery in our hospital during the 5 years 
from January 2006 through December 2010, a total of 
6 patients had noncaseating epithelioid-cell granulo­
mas in the resected lung and dissected lymph nodes. 
Table 1 shows the clinical characteristics of the pa­
tients and the results of examinations to assess sys­
temic sarcoidosis. There were 4 men and 2 women, 
with a mean age of 73.5 years （range, 63 to 79）. The 
histologic type of lung cancer was adenocarcinoma in 4 
patients and squamous-cell carcinoma in 2. The preop­
erative clinical stage of lung cancer as evaluated by 
computed tomography, FDG-PET, and endobronchial 
ultrasonography-guided transbronchial needle aspira­
tion was stage IA in 3 patients, stage IIB in 1 , stage 
IIIA in 1, and stage IIIB in 1. The postoperative histo­
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???????　Clinical Characteristics of Patients
Patient
Age/gender
Tumor
location
Lung cancer
cTNM Stage
Histlogy Complications
Evaluation of sarcoidosis
SUV value of
mediastinal
lymph nodes
（E/D）
ACE
Eye
lesions
Cardiac 
lesions
Activity
①
77 yo F
Rt-S10
T1N0M0 
stage IA
Ad None 6.2/6.6 10.4 None None None
②
75 yo M
Rt-S6
T1N0M0 
stage IA
Sq IP 4.3/4.8 11.2 None
Atrial
extrasystole
None
③
63 yo M
Rt-S1
T3N1M0 
stage IIIA
Sq
Sigmoid
colon cancer
6.9/7.4 18.1 None
Left
ventricular
hypertrophy
None
④
79 yo F
Lt-S8
T1N0M0 
stage IA
Ad RA 3.9/4.0 7.6 None None None
⑤
78 yo M
Rt-S6
T2N3M0 
stage IIIB
Ad None 7.7/10.1 17.0 None None None
⑥
69 yo M
Rt-S2
T3N0M0 
stage IIB
Ad None 4.9/5.0 ND None None None
SUV denotes standardized uptake value；E/D, early and delayed；yo, years old；Ad, adenocarcinoma；Sq, squamous cell 
carcinoma；IP, interstitial pneumonia；RA, rheumatoid arthritis；ND, not done and ACE, angiotensin converting enzyme.
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???????　Results of Immunostaining with PAB Antibodies
Patient
Lung
cancer
LN granuloma
Lung
granuloma Decision
HW macrophage
①
77 yo F
Ad
＋ −
Sarcoidosis
＋ ＋
②
75 yo M
Sq
− −
Sarcoid reaction
＋ ＋
③
63 yo M
Sq
− −
Sarcoid reaction
＋ ＋＋
④
79 yo F
Ad
− −
Sarcoid reaction
＋ −
⑤
78 yo M
Ad
− −
Sarcoid reaction
− −
⑥
69 yo M
Ad
− −
Sarcoid reaction
＋ ＋
Ad denotes adenocarcinoma；Sq, squamous cell carcinoma and HW, 
Hamazaki-Wesenberg bodies.
????????　 P. acnes within noncaseating epithelioid-cell granulomas of the lymph nodes. 
Hematoxylin and eosin staining （left） and immunostaining with PAB antibodies 
（right） are shown pairwise （original magnification, X200 and X400）. Small brown 
round bodies were detected by PAB antibodies within granulomas （arrows）.
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mine whether such patients concurrently have sarcoi­
dosis or sarcoid reactions. Histopathologically, granulo­
mas induced by sarcoid reactions tend to be poorly 
demarcated and scattered, as compared with granulo­
mas induced by sarcoidosis19,20）. However it was diffi­
cult to differentiate between sarcoidosis and sarcoid 
reactions solely on the basis of histopathological find­
ings in these six cases.
The subjects of the present study were six patients 
who underwent surgery for primary lung cancer and 
had noncaseating epithelioid-cell granulomas in the re­
sected lung and dissected lymph nodes, with no evi­
dence of regional lymph-node metastasis. To confirm 
whether the granulomas were induced by sarcoidosis 
or sarcoid reactions associated with lung cancer, the 
involvement of P. acnes was examined on immunos­
taining with PAB antibodies. In five of the six patients, 
PAB-antibody staining was negative in noncaseating 
epithelioid-cell granulomas, ruling out an association 
with P. acnes.
Histopathologically, concurrent sarcoidosis was sus­
pected on the basis of these findings （Fig. 1）. In the 
other five patients, PAB-antibody staining was nega­
tive in granulomas in the lung and dissected lymph 
nodes. These granulomas were therefore attributed to 
sarcoid reactions associated with lung cancer （Fig. 2）. 
In some patients, PAB-antibody staining was weakly 
positive in HW bodies, alveolar macrophages, and lym­
phatic sinuses.
??????????
Sarcoid reactions are found in only about 4 .4％ of 
malignant tumors. In lung cancer, the incidence of sar­
coid reactions around tumors and in regional lymph 
nodes has been reported to range between 2.2％ and 
3.2％10〜12）. Sarcoidosis associated with lung cancer has 
been reported previously13〜17）. In many patients, sar­
coidosis was diagnosed several years before the onset 
of lung cancer, but both diseases were simultaneously 
confirmed in some patients14,18）. It is difficult to deter­
??（1） （2013） 5
?????????　P. acnes within noncaseating epithelioid-cell granulomas of the lungs. Hematoxylin and 
eosin staining （left） and immunostaining with PAB antibodies （right） are shown pairwise 
（original magnification, X100 and X200）. Immunostaining with PAB antibodies were 
negative within granulomas, while small brown round bodies were detected by PAB 
antibodies within alveolar macrophages.
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The mechanism of tumor-associated sarcoid reac­
tions in regional lymph nodes has not yet been eluci­
dated. There have been several speculations concern­
ing the causal relationship between malignant tumors 
and sarcoid reactions21,22）. Sarcoid reactions have been 
considered 1） a localized defense reaction to tumor 
cells themselves, 2） a simple tissue reaction to tumor 
embolism in the lymphatic system or capillaries, and 3） 
an immunologic reaction to substances released from 
the tumors and transported along the lymphatic sys­
tem.
In one patient, PAB-antibody staining was positive 
in granulomas situated in dissected lymph nodes, indi­
cating an association with P. acnes, i.e., the concurrent 
presence of sarcoidosis could not be completely ruled 
out. However, this patient had no evidence suggesting 
active sarcoidosis on the preoperative workup.
Previous studies have suggested three possibilities for 
the relation between sarcoidosis and lung cancer23〜25）：1） 
the two diseases incidentally coexist, 2） the cell-medi­
ated immune abnormalities induced by sarcoidosis are 
involved in the onset of lung cancer, and 3） lung can­
cer originates in fibrous tissue because of sarcoidosis. 
Unanswered questions remain concerning the role of P. 
acnes in the formation of sarcoid granulomas and the 
sensitivity and specificity of imunostaining with PAB 
antibodies against P. acnes. P. acnes is the only micro­
organism isolated from affected lymph nodes in pa­
tients with sarcoidosis and can be effectively isolated 
from sarcoidosis lesions and cultured in large quanti­
ties. However, because P. acnes is part of the normal 
flora of the skin and is isolated from about 25％ of bi­
opsy specimens of lymph nodes in patients without 
sarcoidosis, the causal relation between P. acnes and 
sarcoidosis was difficult to define. In Japan, however, 
comprehensive studies conducted by Eishi et al. estab­
lished the theory that “P. acnes is a cause of sarcoido­
sis, ” and the presence of P. acnes in granulomas in af­
fected organs was shown to be particularly useful for 
the diagnosis of sarcoidosis 9,26〜29）. PAB antibodies, a 
monoclonal antibody specifically against P. acnes, spe­
cifically reacts with lipoteichoic acid and glycolipid an­
tigens distributed from the bacterial cell membrane 
through the cell wall. The rates of PAB-antibody posi­
tivity against granulomas in the lung and lymph nodes 
in patients with sarcoidosis was 48％ for transbronchi­
al lung-biopsy samples, 74％ for video-assisted thorac­
ic surgery lung samples, and 88％ for lymph node 
samples. This antibody never reacts with Mycobacteri-
um tuberculosis, other bacteria, or granulomas induced 
by sarcoid reactions9）. Therefore, positive immunos­
taining with this antibody provides indirect evidence 
of the local presence of P. acnes, suggesting that tissue 
changes are induced by sarcoidosis. Because the re­
sults of PAB-antibody testing were negative in nonca­
seating epithelioid-cell granulomas in five of our six 
patients, the associated tissue changes were attributed 
to sarcoid reactions caused by lung cancer.
The developmental mechanism of sarcoid reactions 
associated with lung cancer and other malignant tu­
mors remains unclear. Our results suggest that the 
participation of P. acnes in sarcoid reactions accompa­
nying lung cancer is rare, even when granulomas are 
present in the lung as well as regional lymph nodes. 
Sarcoid reactions are found in only 2.2％ to 3.2％ of all 
cases of lung cancer. In patients who have enlarged 
lymph nodes showing increased uptake of FDG on 
PET, the absence of malignant cells on histopathologi­
cal examination strongly suggests the possibility of 
sarcoid reactions, and this may have important conse­
quences for tumor staging. However, because we stud­
ied only six patients, further studies of larger numbers 
of patients are necessary to confirm our results.
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